May 27 General Motors Co said on Saturday that proxy advisory firm Institutional Shareholder Services has recommended that shareholders vote against a slate of directors proposed by hedge fund Greenlight Capital and reject the hedge fund's plan to divide GM shares into two classes.
The advice from ISS is a setback for Greenlight and its manager David Einhorn. They have argued that GM shares are undervalued and would be more attractive if the company divided its common stock into shares that pay a dividend and shares that would reflect the automaker's growth potential.
GM shares closed Friday at $33.07, just seven cents above the 2010 initial public offering price for shares issued following the automaker's federally funded bankruptcy.
A representative for Greenlight wasn't immediately available for comment.
Greenlight also has proposed a slate of three candidates for GM's board of directors. They are Leo Hindery Jr., a veteran telecommunications industry executive, Greenlight executive Vinit Sethi, and William N. Thorndike Jr., managing director of Housatonic Partners, a private equity firm.
On Friday, advisory firm Glass Lewis also advised against Greenlight's nominees for the automaker's board and its plan for restructuring GM's shares.
Glass Lewis and ISS have agreed with GM management's view that Greenlight's plan to restructure the company's common stock creates risks that outweigh its potential benefits.
According to GM, ISS said Greenlight had not made "a compelling case that change at the board level focusing on the implementation of its proposal is warranted.”
GM's annual meeting is June 6 in Detroit. (Reporting By Joe White; Editing by W Simon)
UPDATE 1-UK Stocks-Factors to watch on June 29
June 29 Britain's FTSE 100 index is seen opening up 37 points at 7,424 on Thursday, according to financial bookmakers, with futures up 0.52 percent ahead of the cash market open.
AstraZeneca, Chi-Med take kidney cancer drug into final testing
LONDON, June 29 AstraZeneca and Hutchison China MediTech said on Thursday they had initiated a global late-stage clinical trial of the experimental drug savolitinib in a relatively rare type of kidney cancer.